Rius Medical is a biotechnology company that develops cell therapies for cancer, enzyme deficiency diseases and for the treatment of autoimmune, metabolic and other diseases. Through its B2B Solution emphasis, Rius Medical aims to serve customers in Europe such as France (Erytech Pharma), Switzerland (Orphan Technologies) and Denmark (Novo Nordisk) as well as in the United States of America (Rubius Therapeutics). Think of Rius Medical as a contractor providing third parties with "upgrade software." Just as Microsoft is a provider to computer companies - IBM, DELL, Toshiba, etc. with it’s operating system, Rius Medical is bringing to Erytech Pharma, Rubius Therapeutics, etc. a new "gene technology" operating system.

Immunological Tolerance as the Cure to type 1 diabetes:

The absence of regulatory T cells (Tregs) leads to autoimmune diseases like type 1 diabetes mediated by proinflammatory T cells (Teff) that destroys insulin producing islet beta cells ¹. Carolin Daniel at Helmholtz Zentrum Munich’s Institute of Diabetes Research is studying “Type 1 Diabetes Immunological Tolerance”.

Rius Medical is developing proprietary cell lines for drug delivery. What we do are novel protein therapeutics and a drug delivery technology combine. The Cure to type 1 diabetes is stem cells-derived red blood cells modified to carry disease-specific antigens as March 2017 reported by Rubius Therapeutics ². Rius Medical is an upgrade on Rubius Therapeutics. To understand that, one has to be aware of “High Insulin Prices driving Diabetics to Take Extreme Measures ³”! Through a new "gene technology" operating system, Rius Medical brings an affordable and sustainable way to provide affordable medication to patients. This is best exemplified in Rius Medical targeting autoimmune disease, type 1 diabetes!

The Rius Medical project is available to all investors, as published on EuroQuity ⁴ and European Investment Project Portal (EIPP) ⁵. From EuroQuity, the Resource Link Consulting Group expressed its interest in Rius Medical and issued a Memorandum of Understanding. Resource Link Consulting Group agreed on a total investment value of 1.000.000 € against 20% ownership as a silent partner to Rius Medical. A 45.000 € Bank Loan from European Investment Bank (EIB) through EIB financing partner Commerzbank www is an option as depicted by Commerzbank Investment Finance ⁶.

To a 45.000 € Convertible Loan option, Rius Medical is issuing a 45.000 € Convertible Loan to business angels due to upfront fees of 44.996 € prior to accessing the 1.000.000 € equity capital. This 45.000 € Convertible Loan at a discounted rate of 0,50 € per share, implies 4.860.000 € financial benefits on FIVE products or 945.000 € financial benefits on TWO products at 3 years to early investors on the convertible loan. Presently Rius Medical is considering splitting the 45.000 € Convertible Loan among three or more Business Angels? As a business angels, what is your desired contribution to this project?

Best regards,

Denis

Denis Demarais (BSc)

Founder, CEO and Chief Scientific Officer

Lead Investor Resource Link Consulting Group agreed to a total investment value of 1.000.000 € against 20% ownership as a silent partner to Rius Medical.

Rius Medical is issuing a 45.000 € Convertible Loan to Business Angels, due to upfront fees of 44.996 € before the 1.000.000 € capital can be accessed. This 45.000 € Convertible Loan at a discounted rate of 0,50 € per share brings 4.860.000 € in financial benefits on FIVE products, if not 945.000 € in financial benefits on TWO products at 3 years for early investors of the Convertible Loan.

Rius Medical’s alignment to European Investment Bank (EIB)

Building on medical research of the past decade since 2006, Rius Medical implements innovations that provide sustainable health services on diseases having the highest expected economic value for society ¹. For example, this is highlighted in red blood cells for antigen delivery as the cure for type 1 diabetes.

Universal access with effective, safe and affordable preventative and curative therapeutic assets:

Rius Medical’s cutting-edge proprietary cell-engineering platform genetically engineers healthy donor-derived blood forming stem cells (of blood Group type O negative, universal donor) from either adult bone marrow or umbilical cord blood to expand long-term in laboratory bioreactor culture and on-demand generate red blood cells inclusive of desired therapeutic proteins either an enzyme or antigen as therapeutic. The product is selective, potent, ready-to-use, off-the-shelf allogeneic cellular therapy.

In Rius Medical, EIB will find an economically and financially sustainable health sector project, based on best practices. Rius Medical develops proprietary cell lines for drug delivery in the field of Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes.

Do reach out for further information at “denisdemarais@riusmedical.de” if interested.

The Business Plan “red blood cells for drug delivery” depicts an investment opportunity with strong return on Investment at year 3. For early investors’ review of Rius Medical, here in the Business Plan you have all information provided to investors interested in forming a syndicate. 

Gaining traction in cell therapy is gene engineering. You see that in CAR-T /CAR-NK cell therapies with viral vectors addition of CAR genes. And you can see that also with iPS derived cell therapies like Bayer acquisition of BlueRock Therapeutics ¹. Rius Medical takes advantage of that and goes THREE steps further. (1) Yes we add genes for cell therapies. (2) Furthermore, what is unique in our approach is that we are the only company using a “master template” that significantly reduce Industry Challenges relative to our competitors e.g. Erytech Pharma or Rubius Therapeutics. (3) The three of us combine (Rius Medical, Erytech Pharma and Rubius Therapeutics) have the same product - red blood cells for drug delivery. What makes Rius Medical unique is that our gene engineering approach brings the only solution to Industry Challenges (i.e. enables market entry with strong profit earnings). Despite successful phase III clinical data ² with acute lymphoblastic leukemia, Erytech Pharma discontinued it’s Leukaemia program in June 2018 ³ and instead shifted focus to solid tumor, now under phase III clinical studies in pancreatic cancer. 

Simply having a higher price tag is not attracting customers. Market approved CAR-T cells by Novartis and Gilead Sciences illustrate that ⁴. It is working - proof of concept is established in engineering stem cells and there are thousands of research scientists around the world doing the same thing I did in stem cells research, i.e. culture stem cells into cellular therapies that work under academia settings! Those that were able to get financing are demonstrating that in clinical studies (again Erytech Pharma and Rubius Therapeutics). Nonetheless Industry Challenges ⁵ are a problem we as scientists face in developing cell therapies. That’s why I left academia to start Rius Medical that offers a solution to the Industry Challenges. The business opportunity here with FIVE assets, brings 54 million euro Return on Investment to investors at year 3 on up to 1 million euro equity capital investment. 

It would be helpful to know how early investors wish to move forward. After all, there is no innovation without collaboration! Are you against forming a syndicate of investors?

Many thanks and warmest regards, 

Denis Demarais

Rius Medical based in Germany has a technology to upgrade French base company Erytech Pharma using red blood cells for drug delivery of therapeutic protein L-Asparaginase, thus targeting multiple cancers.

To the disappointment of Recordati an investor to Erytech Pharma, Erytech Pharma discontinued it’s Leukaemia program in June 2018 despite successful phase III clinical data with Acute Lymphoblastic Leukemia (ALL) and instead shifted focus to solid tumor, now under phase III clinical studies. Cell & Gene Therapy will shape the future of medicine, when novel technologies proceed beyond the primary goals of safety and efficacy. Uneconomical manufacturing is an industry challenge and represents a major roadblock to the sustainable commercialisation of cellular products. The solution, Rius Medical technology engineers stem cells into therapeutic products and provides a Business-to-Business solution to France-based Erytech Pharma for upgraded red blood cells that do more than simply carry oxygen. 

https://seekingalpha.com/news/3366101-erytech-pharma-minus-29-percent-stopping-development-key-drug?dr=1#email_link

Furthermore, from the perspective of French pharmaceutical company Servier Laboratories, seeking opportunities in FIVE areas of research and development being cardiovascular diseases, cancer, diabetes, neuropsychiatric diseases like multiple sclerosis and immune-inflammatory diseases; Rius Medical platform technology for the delivery of therapeutic protein encapsulated in red blood cells addresses all FIVE of them. The upgrade there is with antigen-loaded red blood cells against Autoimmune diseases.

As a young company not doing incremental improvements, Rius Medical develops a platform technology to engineer stem cells for next generation therapeutics as core business. Rius Medical mission is to make its highly innovative platform technology available at 3 years to pharmaceutical and biotech partners. In addressing Ageing and Ageing-related diseases such as cardiovascular disease, Rius Medical is a Deep tech company bringing innovation to an aging society with Deep Tech for healthcare.

This is the path of Rius Medical making the French economy more competitive by boosting French companies Erytech Pharma and Servier Laboratories in bringing their products to market following an upgrade in technology. For the French economy, that translates into local Job creation and a healthier work force within an ageing population.

Denis Demarais (BSc)
Founder, CEO and Chief Scientific Officer